Clinical Trials Browser

Ovarian Neoplasms × mirvetuximab soravtansine × 30 days × Clear all

NCT05887609 2026-06-04

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07059845 2026-06-04

FLORENZA

Phase 2 Recruiting

Ovarian Neoplasms

NCT05445778 2026-06-02

GLORIOSA

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms